Abstract
Background To inform public health policies regarding disease management, it is crucial to comprehend the prevalence and mortality rates linked to various stages of Cardiovascular-Kidney-Metabolic (CKM) syndrome.
Methods A longitudinal study was conducted using National Health and Nutrition Examination Survey (NHANES) data (1999-2018) from 50,624 U.S. adults, defining CKM syndrome stages based on the 2023 American Heart Association (AHA) Presidential Advisory Statement. The investigation aimed to assess changes in 10-and 15-year adjusted cumulative incidences of cardiovascular mortality with each CKD syndrome stage and describe the cross-sectional prevalence of CKM syndrome from 1999 to 2020.
Results CKM syndrome prevalence by stage was as follows: Stage 0, 12.5% (95% CI, 12.0-12.9); Stage 1, 16.7% (95% CI, 16.2-17.2); Stage 2, 40.0% (95% CI, 38.4-39.6); Stage 3, 22.9% (95% CI, 22.5-23.4); Stage 4, 8.9% (95% CI, 8.6-9.2). Over a median 9.5-year follow-up, 2,557 participants experienced cardiovascular death. The proportion of participants in Stages 0 and 3 decreased, while Stage 1 increased. The 15-year adjusted cumulative incidences of cardiovascular mortality were: Stage 0, 4.8% (95% CI 3.1-6.6); Stage 1, 5.3% (95% CI 4.0-6.6); Stage 2, 7.9% (95% CI 8.1-10.3); Stage 3, 9.2% (95% CI 8.1-10.3); Stage 4, 15.6% (95% CI 14.7-16.6). The absolute risk difference between CKM Stage 4 and Stage 0 at 15 years was 10.8% (95% CI 8.8-12.8).
Conclusions Our findings showed a graded increase in cardiovascular mortality associated with each CKM stage. The trends observed by stage prevalence emphasize critical opportunities for stabilizing risk factors, thereby preventing adverse cardiovascular outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R38HL143584.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data analyzed in this manuscript are publicly available at https://wwwn.cdc.gov/nchs/nhanes/default.aspx.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data are available at https://wwwn.cdc.gov/nchs/nhanes/default.aspx
